On March 27, 2018 STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, reported that it has won the Life Science Innovation Award at the Business Weekly Awards ceremony (Press release, STORM Therapeutics, MAR 27, 2018, View Source [SID1234561045]). Held at Queen’s College, Cambridge, the Awards Dinner attracts entries from across the East of England and is the longest-running B2B competition in the UK. The Awards pride themselves on early identification of world-leading businesses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STORM Therapeutics was recognised by the judges for leading the field in a highly innovative area of drug discovery which has the potential to target novel disease mechanisms through the inhibition of RNA modifying enzymes.

Commenting on the award, Keith Blundy, CEO of STORM Therapeutics said: "We are very pleased to have been recognized for the Life Science Award, voted for by our peers in Cambridge. It is a credit to the team and our Investors, and a strong endorsement of STORM’s pioneering drug discovery programmes. As the first company tackling disease through harnessing the power of RNA epigenetics, we believe we are well positioned to build a world leading company."